The standard treatment for non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guérin (BCG). However, despite it being effective, many patients experience recurrences, and others become unresponsive. The activation of the intracellular transmembrane receptor stimulator of interferon genes (STING) has shown antitumoral effects in murine cancer models.
Rappta Therapeutics Oy has signed an exclusive global license agreement with Springworks Therapeutics Inc. for RPT-04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Springworks will be responsible for global development and commercialization of RPT-04402, now named SW-3431, and expects to file an IND application by year-end.
Centre National de la Recherche Scientifique (CNRS) and Université Grenoble Alpes have developed new iridium complexes acting as photosensitizers for photodynamic therapy and reported to be potentially useful for the treatment of cancer.
Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers retaining wild-type p53.
Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors BI-2493 and BI-2865, both being developed for the treatment of cancer. Previous research has shown that these pan-KRAS inhibitors target KRAS in the inactive OFF state, while sparing HRAS and NRAS.
An exclusive licensing agreement with Insilico Medicine Inc. grants Menarini’s Stemline Therapeutics Inc. the global rights to develop and commercialize a preclinical small molecule for high unmet needs in oncology.
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYS-6041, an antibody-drug conjugate, for advanced solid tumors.
Normunity Inc. has closed a $75 million series B financing to support its pipeline of novel anticancer therapies targeting untapped drug mechanisms. Proceeds from the financing will be used to advance Normunity’s lead program, NRM-823, a first-in-class T-cell engager.
RSS
